Nadia Demarteau1, Baudouin Standaert. 1. Health Economics, GlaxoSmithKline Biologicals, Av. Fleming 20, Wavre, Belgium. nadia.x.demarteau@gskbio.com
Abstract
OBJECTIVE: Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS: A Markov cohort model reproducing the natural history of HPV infections, screening and vaccination, is adapted to country-specific data. Two hypothetical HPV vaccines (VA and VB) are compared. At baseline VA provides lifetime protection against HPV-16 and 10-year protection against HPV-18 before waning. VB is the same as VA with a 10-year protection against HPV-6 and 11. Sustained- and cross-protection is varied over wide ranges in VA to define the levels that could make VA cost-effective or dominant compared with VB. RESULTS: Under baseline conditions VB dominates VA. VA becomes cost-effective when the difference in cross-protection alone reaches 13-15% (undiscounted), and 22-44% (discounted). A combination of sustained- and cross-protection is required for VA to dominate VB (discounted). The results are dependent upon country, the base-case value and the discount applied. CONCLUSION: Realistic additional sustained- and cross-protection in one HPV vaccine may confer benefits that offset the economic value of protection against low-risk HPV in the other. The results are country specific.
OBJECTIVE: Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS: A Markov cohort model reproducing the natural history of HPV infections, screening and vaccination, is adapted to country-specific data. Two hypothetical HPV vaccines (VA and VB) are compared. At baseline VA provides lifetime protection against HPV-16 and 10-year protection against HPV-18 before waning. VB is the same as VA with a 10-year protection against HPV-6 and 11. Sustained- and cross-protection is varied over wide ranges in VA to define the levels that could make VA cost-effective or dominant compared with VB. RESULTS: Under baseline conditions VB dominates VA. VA becomes cost-effective when the difference in cross-protection alone reaches 13-15% (undiscounted), and 22-44% (discounted). A combination of sustained- and cross-protection is required for VA to dominate VB (discounted). The results are dependent upon country, the base-case value and the discount applied. CONCLUSION: Realistic additional sustained- and cross-protection in one HPV vaccine may confer benefits that offset the economic value of protection against low-risk HPV in the other. The results are country specific.
Authors: Ariel Esteban Bardach; Osvaldo Ulises Garay; María Calderón; Andrés Pichón-Riviére; Federico Augustovski; Sebastián García Martí; Paula Cortiñas; Marino Gonzalez; Laura T Naranjo; Jorge Alberto Gomez; Joaquín Enzo Caporale Journal: BMC Public Health Date: 2017-02-02 Impact factor: 3.295
Authors: Maria Julieta Germar; Carrie Purugganan; Ma Socorro Bernardino; Benjamin Cuenca; Y-Chen Chen; Xiao Li; Georges Van Kriekinge; I-Heng Lee Journal: Hum Vaccin Immunother Date: 2017-01-11 Impact factor: 3.452
Authors: Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau Journal: BMC Public Health Date: 2012-10-13 Impact factor: 3.295
Authors: Georges Van Kriekinge; Woo-Yun Sohn; Syed Mohamed Aljunid; Ruey Soon; Chee-Meng Yong; Jing Chen; I-Heng Lee Journal: Asian Pac J Cancer Prev Date: 2018-04-25